Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1991 Oct;59(10):3610–3618. doi: 10.1128/iai.59.10.3610-3618.1991

Protective ribosomal preparation from Shigella sonnei as a parenteral candidate vaccine.

V I Levenson 1, T P Egorova 1, Z P Belkin 1, V G Fedosova 1, J L Subbotina 1, E Z Rukhadze 1, E K Dzhikidze 1, Z K Stassilevich 1
PMCID: PMC258928  PMID: 1716612

Abstract

A parenteral Shigella ribosomal vaccine (SRV) was investigated in animals for safety, antibody-inducing capacity, and protective activity. Ribosomal preparations from a Shigella sonnei phase I avirulent strain were obtained and shown to possess chemical, sedimentation, and other properties typical of bacterial ribosomes. No endotoxin contamination was revealed by a ketodeoxyoctonate assay, although the presence of some kind of O antigen was evidenced by serological findings and the high activity of SRV in inducing the O-antibody response and immunological memory in animals. SRV was nontoxic in mice, guinea pigs, and monkeys and induced no local reactions when injected subcutaneously in reasonable doses. Significant protection against a local Shigella infection (Sereny test) was seen in guinea pigs injected with SRV (efficiency index, about 60%) and the specificity of the protection was evident from cross-challenge experiments. The protective efficiency of SRV was especially high in rhesus monkeys challenged orally with virulent Shigella cells (89%, as calculated from the summarized data of several experiments in 71 animals). Protection in monkeys was long lasting and could be demonstrated several months after injection of SRV. An inexpensive technique can be used for the production of SRV on a large scale. The high immunogenicity of SRV is discussed in terms of the amplifying effect of the ribosome, which serves as a delivery system for polysaccharide O antigen. Further study of SRV as a candidate vaccine for humans seems justified by the data obtained.

Full text

PDF

Images in this article

3613Image
on p.3613

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ANACKER R. L., FINKELSTEIN R. A., HASKINS W. T., LANDY M., MILNER K. C., RIBI E., STASHAK P. W. ORIGIN AND PROPERTIES OF NATURALLY OCCURRING HAPTEN FROM ESCHERICHIA COLI. J Bacteriol. 1964 Dec;88:1705–1720. doi: 10.1128/jb.88.6.1705-1720.1964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Adamus G., Mulczyk M., Witkowska D., Romanowska E. Protection against keratoconjunctivitis shigellosa induced by immunization with outer membrane proteins of Shigella spp. Infect Immun. 1980 Nov;30(2):321–324. doi: 10.1128/iai.30.2.321-324.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ahmed Z. U., Sarker M. R., Sack D. A. Protection of adult rabbits and monkeys from lethal shigellosis by oral immunization with a thymine-requiring and temperature-sensitive mutant of Shigella flexneri Y. Vaccine. 1990 Apr;8(2):153–158. doi: 10.1016/0264-410x(90)90139-d. [DOI] [PubMed] [Google Scholar]
  4. BECKMANN I., SUBBAIAH T. V., STOCKER B. A. ROUGH MUTANTS OF SALMONELLA TYPHIMURIUM. II. SEROLOGICAL AND CHEMICAL INVESTIGATIONS. Nature. 1964 Mar 28;201:1299–1301. doi: 10.1038/2011299a0. [DOI] [PubMed] [Google Scholar]
  5. Barber C., Eylan E., Keydar J. Origine ribosomale des protéines communes des E. coli et des Salmonella. Pathol Microbiol (Basel) 1968;32(1):15–23. [PubMed] [Google Scholar]
  6. Black R. E., Levine M. M., Clements M. L., Losonsky G., Herrington D., Berman S., Formal S. B. Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine. J Infect Dis. 1987 Jun;155(6):1260–1265. doi: 10.1093/infdis/155.6.1260. [DOI] [PubMed] [Google Scholar]
  7. Blaser M. J., Hale T. L., Formal S. B. Recurrent shigellosis complicating human immunodeficiency virus infection: failure of pre-existing antibodies to confer protection. Am J Med. 1989 Jan;86(1):105–107. doi: 10.1016/0002-9343(89)90239-8. [DOI] [PubMed] [Google Scholar]
  8. Cohen D., Green M. S., Block C., Rouach T., Ofek I. Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population. J Infect Dis. 1988 May;157(5):1068–1071. doi: 10.1093/infdis/157.5.1068. [DOI] [PubMed] [Google Scholar]
  9. Dussourd d'Hinterland L. Ribosomal vaccines: introduction to the study of ribosomal vaccines. Arzneimittelforschung. 1980;30(1A):122–125. [PubMed] [Google Scholar]
  10. Egorova T. P., Sazykina S. Iu, Fedosova V. G., Lebenson V. I. O-spetsificheskii L-gapten v sostave Shigella sonnei. Zh Mikrobiol Epidemiol Immunobiol. 1989 Nov;(11):8–13. [PubMed] [Google Scholar]
  11. Eisenstein T. K. Evidence for O antigens as the antigenic determinants in "ribosomal" vaccines prepared from Salmonella. Infect Immun. 1975 Aug;12(2):364–377. doi: 10.1128/iai.12.2.364-377.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Expert-Bezançon A., Guérin M. F., Hayes D. H., Legault L., Thibault J. Preparation of E. coli ribosomal subunits without loss of biological activity. Biochimie. 1974;56(1):77–89. doi: 10.1016/s0300-9084(74)80357-3. [DOI] [PubMed] [Google Scholar]
  13. Formal S. B., Hale T. L., Kapfer C., Cogan J. P., Snoy P. J., Chung R., Wingfield M. E., Elisberg B. L., Baron L. S. Oral vaccination of monkeys with an invasive Escherichia coli K-12 hybrid expressing Shigella flexneri 2a somatic antigen. Infect Immun. 1984 Nov;46(2):465–469. doi: 10.1128/iai.46.2.465-469.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Formal S. B., Maenza R. M., Austin S., LaBrec E. H. Failure of parenteral vaccines to protect monkeys against experimental shigellosis. Proc Soc Exp Biol Med. 1967 Jun;125(2):347–349. doi: 10.3181/00379727-125-32087. [DOI] [PubMed] [Google Scholar]
  15. Fournier J. M., Jolivet-Reynaud C., Riottot M. M., Jouin H. Murine immunoprotective activity of Klebsiella pneumoniae cell surface preparations: comparative study with ribosomal preparations. Infect Immun. 1981 May;32(2):420–426. doi: 10.1128/iai.32.2.420-426.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Germanier R. Oral vaccination against enteric bacterial infections: an overview. Infection. 1984 Mar-Apr;12(2):138–142. doi: 10.1007/BF01641699. [DOI] [PubMed] [Google Scholar]
  17. Gregory R. L., Michalek S. M., Shechmeister I. L., McGhee J. R. Effective immunity to dental caries: protection of gnotobiotic rats by local immunization with a ribosomal preparation from Streptococcus mutans. Microbiol Immunol. 1983;27(9):787–800. doi: 10.1111/j.1348-0421.1983.tb00644.x. [DOI] [PubMed] [Google Scholar]
  18. Gregory R. L. Microbial ribosomal vaccines. Rev Infect Dis. 1986 Mar-Apr;8(2):208–217. doi: 10.1093/clinids/8.2.208. [DOI] [PubMed] [Google Scholar]
  19. Hale T. L., Formal S. B. Oral shigella vaccines. Curr Top Microbiol Immunol. 1989;146:205–211. doi: 10.1007/978-3-642-74529-4_22. [DOI] [PubMed] [Google Scholar]
  20. Istrati G., Meitert T., Ciufeco C. Recherches sur l'immunité active de l'homme dans la dysenterie bacillaire. 3. Maintien du caractère non-pathogène de la souche Sh. flexneri 2a TXXXII administrée "per os" à des volontaires. Arch Roum Pathol Exp Microbiol. 1965 Sep;24(3):677–686. [PubMed] [Google Scholar]
  21. Janda J., Work E. A colorimetric estimation of lipopolysaccharides. FEBS Lett. 1971 Sep 1;16(4):343–345. doi: 10.1016/0014-5793(71)80386-1. [DOI] [PubMed] [Google Scholar]
  22. Johnson W. Ribosomal vaccines. I. Immunogenicity of ribosomal fractions isolated from Salmonella typhimurium and Yersinia pestis. Infect Immun. 1972 Jun;5(6):947–952. doi: 10.1128/iai.5.6.947-952.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kontrohr T. A comparative immunochemical study of Shigella sonnei haptene polysaccharides. Ann Immunol Hung. 1972;16(0):249–254. [PubMed] [Google Scholar]
  24. Labrec E. H., Schneider H., Magnani T. J., Formal S. B. EPITHELIAL CELL PENETRATION AS AN ESSENTIAL STEP IN THE PATHOGENESIS OF BACILLARY DYSENTERY. J Bacteriol. 1964 Nov;88(5):1503–1518. doi: 10.1128/jb.88.5.1503-1518.1964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Levenson V. I., Chernokhvostova E. V., Lyubinskaya M. M., Salamatova S. A., Dzhikidze E. K., Stasilevitch Z. K. Parenteral immunization with Shigella ribosomal vaccine elicits local IgA response and primes for mucosal memory. Int Arch Allergy Appl Immunol. 1988;87(1):25–31. doi: 10.1159/000234644. [DOI] [PubMed] [Google Scholar]
  26. Levenson V. I., Egorova T. P. Polysaccharide nature of O antigen in protective ribosomal preparations from Shigella: experimental evidence and implications for the ribosomal vaccine concept. Res Microbiol. 1990 Jul-Aug;141(6):707–720. doi: 10.1016/0923-2508(90)90065-x. [DOI] [PubMed] [Google Scholar]
  27. Levenson V. I., Gorach G. G., Dadashev S. Ia, Rukhadze E. Z. Vydelenie i ochistka bakterial'nykh ribosom ot éndotoksina s pomoshch'iu poliétilenglikolia. Zh Mikrobiol Epidemiol Immunobiol. 1984 May;(5):20–25. [PubMed] [Google Scholar]
  28. Levenson V. I., Rukhadze E. Z., Fedosova V. G., Dzhikidze E. K., Stasilevich Z. K. Biologicheskie svoistva ribosomal'noi vaktsiny iz S. sonnei, poluchennoi metodom fraktsionirovaniia poliétilenglikolem. Zh Mikrobiol Epidemiol Immunobiol. 1984 Nov;(11):77–81. [PubMed] [Google Scholar]
  29. Levine M. M. Bacillary dysentery: mechanisms and treatment. Med Clin North Am. 1982 May;66(3):623–638. doi: 10.1016/s0025-7125(16)31411-0. [DOI] [PubMed] [Google Scholar]
  30. Levy R., Segal E., Eylan E. Protective immunity against murine candidiasis elicited by Candida albicans ribosomal fractions. Infect Immun. 1981 Mar;31(3):874–878. doi: 10.1128/iai.31.3.874-878.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Lindberg A. A., Holme T., Hellerqvist C. G., Svensson S. Studies of a li-hapten isolated from cell-walls of the rough mutant Salmonella typhimurium 395 MR10. Acta Pathol Microbiol Scand B Microbiol Immunol. 1972;80(5):743–750. doi: 10.1111/j.1699-0463.1972.tb00202.x. [DOI] [PubMed] [Google Scholar]
  32. Lindberg A. A., Kärnell A., Stocker B. A., Katakura S., Sweiha H., Reinholt F. P. Development of an auxotrophic oral live Shigella flexneri vaccine. Vaccine. 1988 Apr;6(2):146–150. doi: 10.1016/s0264-410x(88)80018-5. [DOI] [PubMed] [Google Scholar]
  33. Liubinskaia M. M., Rukhadze E. Z., Chernokhvostova E. V., Levenson V. I. Mestnyi immunitet pri parenteral'noi immunizatsii morskikh svinok ribosomal'noi dizenteriinoi vaktsinoi. Zh Mikrobiol Epidemiol Immunobiol. 1985 Jul;(7):55–59. [PubMed] [Google Scholar]
  34. Meitert T. Antidysentery immunoprophylaxis in the light of current data about the pathogenicity of Shigella and the antidysentery immunity. Arch Roum Pathol Exp Microbiol. 1984 Jul-Dec;43(3-4):195–230. [PubMed] [Google Scholar]
  35. Mel D. M., Terzin A. L., Vuksić L. Studies on vaccination against bacillary dysentery. 3. Effective oral immunization against Shigella flexneri 2a in a field trial. Bull World Health Organ. 1965;32(5):647–655. [PMC free article] [PubMed] [Google Scholar]
  36. Mills S. D., Sekizaki T., Gonzalez-Carrero M. I., Timmis K. N. Analysis and genetic manipulation of Shigella virulence determinants for vaccine development. Vaccine. 1988 Apr;6(2):116–122. doi: 10.1016/s0264-410x(88)80012-4. [DOI] [PubMed] [Google Scholar]
  37. Misfeldt M. L., Johnson W. Identification of protective cell surface proteins in ribosomal fractions from Salmonella typhimurium. Infect Immun. 1979 Jun;24(3):808–816. doi: 10.1128/iai.24.3.808-816.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Misfeldt M. L., Johnson W. Role of endotoxin contamination in ribiosomal vaccines prepared from Salmonella typhimurium. Infect Immun. 1977 Jul;17(1):98–104. doi: 10.1128/iai.17.1.98-104.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Mulczyk M., Adamus G., Witkowska D. Protective properties of peptidoglycan associated protein of Shigella flexneri. Arch Immunol Ther Exp (Warsz) 1984;32(5):631–635. [PubMed] [Google Scholar]
  40. OSSERMAN E. F. A modified technique of immunoelectrophoresis facilitating the identification of specific precipitin arcs. J Immunol. 1960 Jan;84:93–97. [PubMed] [Google Scholar]
  41. Robbins J. B., Schneerson R. Polysaccharide-protein conjugates: a new generation of vaccines. J Infect Dis. 1990 May;161(5):821–832. doi: 10.1093/infdis/161.5.821. [DOI] [PubMed] [Google Scholar]
  42. SCHEIDEGGER J. J. Une micro-méthode de l'immuno-electrophorèse. Int Arch Allergy Appl Immunol. 1955;7(2):103–110. [PubMed] [Google Scholar]
  43. SERENY B. Experimental shigella keratoconjunctivitis; a preliminary report. Acta Microbiol Acad Sci Hung. 1955;2(3):293–296. [PubMed] [Google Scholar]
  44. YOUMANS A. S., YOUMANS G. P. IMMUNOGENIC ACTIVITY OF A RIBOSOMAL FRACTION OBTAINED FROM MYCOBACTERIUM TUBERCULOSIS. J Bacteriol. 1965 May;89:1291–1298. doi: 10.1128/jb.89.5.1291-1298.1965. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES